Lipidology

Ultragenyx Launches Evkeeza® (evinacumab for injection) in Canada for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)

Retrieved on: 
Monday, September 25, 2023
Diet, Lipidology, Department of Medicine – University of Pamplona, ANGPTL3, Patient, Disease, Ageing, Health Canada, Pharmaceutical industry, Evinacumab

Evkeeza® was approved by Health Canada as an adjunct to diet and other low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients aged 5 years and older with homozygous familial hypercholesterolemia (HoFH) and will be commercially available in Canada effective 25-November-2023.

Key Points: 
  • Evkeeza® was approved by Health Canada as an adjunct to diet and other low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients aged 5 years and older with homozygous familial hypercholesterolemia (HoFH) and will be commercially available in Canada effective 25-November-2023.
  • Evkeeza is a first-of-its-kind treatment for HoFH and is the first monoclonal antibody inhibiting the angiopoietin-like 3 protein (ANGPTL3).
  • The treatment is now available to prescribe for patients with HoFH in Canada.
  • “The approval and launch of Evkeeza in Canada for the treatment of homozygous familial hypercholesterolemia exemplifies our commitment to bring innovative therapies for people living with rare and ultrarare genetic diseases,” said Monty Keast, Vice President and General Manager at Ultragenyx Canada.

Boston Heart Diagnostics Launches LipidSeq™-- An NGS Test for Common Genetic Disorders of Lipid Metabolism

Retrieved on: 
Wednesday, August 17, 2022
LCAT, Robarts Research Institute, Triglyceride, Cardiovascular disease, Multimedia, Disorder, Risk, Apolipoprotein, Lists of diseases, Hypercholesterolemia, HDL, Lipid metabolism, Tangier disease, Hypertriglyceridemia, Patient, View, NGS, Kidney, Sitosterolemia, Mutation, Lipidology, Health, Disease, Health care, Pharmaceutical industry, Eurofins Scientific, Familial dysbetalipoproteinemia

This saliva-based NGS test identifies the most common genetic causes of lipid and lipoprotein disorders.

Key Points: 
  • This saliva-based NGS test identifies the most common genetic causes of lipid and lipoprotein disorders.
  • Boston Heart Diagnostics announces the launch of LipidSeq, a revolutionary genetic test for cardiovascular disease.
  • Boston Heart is the only commercial laboratory able to test biochemical and genetic contributors when diagnosing inherited disorders of lipid metabolism (Reference: Schaefer EJ, Geller AS, Endress G. The biochemical and genetic diagnosis of lipid disorders.
  • For more information on Boston Heart Diagnostics, please visit www.BostonHeartDiagnostics.com
    View original content to download multimedia: https://www.prnewswire.com/news-releases/boston-heart-diagnostics-launch...

Mobile Cardiac Testing Unit Saves the Lives of Four Elizabeth Police Department Officers

Retrieved on: 
Wednesday, March 9, 2022
Hypertension, Risk, Department, Infarction, National Association Medical Staff Services, Sleep deprivation, Diabetes, Pima County Sheriff's Department, Woman, Law enforcement, Hyperlipidemia, Police, ACD, Prison, Stroke, Man, Cardiovascular disease, Port Authority of New York and New Jersey Police Department, Death, Disease, Elizabeth, Fire department, Medical device, Lipidology

ELIZABETH, N.J., March 9, 2022 /PRNewswire/ --On February 23rd and 24th, the Advanced Cardiovascular Diagnostic (ACD) Mobile Testing Unit performed cardio stress testing for the Police Officers of the Elizabeth, New Jersey Police Department.

Key Points: 
  • ELIZABETH, N.J., March 9, 2022 /PRNewswire/ --On February 23rd and 24th, the Advanced Cardiovascular Diagnostic (ACD) Mobile Testing Unit performed cardio stress testing for the Police Officers of the Elizabeth, New Jersey Police Department.
  • During the examination period, the medical staff determined that four Police Officers were in need of life-saving care.
  • Because it could be difficult for law enforcement and first responders to schedule routine cardiovascular testing, by bringing the Mobile Cardio Unit to their facilities, ACD hopes to save more lives.
  • Vice president Mike Barros of the Elizabeth Police Department Union said, "I am grateful to Advanced Cardio Diagnostic Mobile Testing for the professional life saving care that our Police Department Facility received.

Anthony P. Morise is being recognized by Continental Who's Who

Retrieved on: 
Friday, July 9, 2021
Biochemistry, Lipidology, Lipids, Cardiology, American Board of Internal Medicine, Biology, Branches of biology, Life sciences

Va., July 9, 2021 /PRNewswire/ -- Anthony P. Morise is being recognized by Continental Who's Who as a Trusted Cardiologist for his exceptional work in the field of Lipidology and Cardiology and in recognition of his work at West Virginia University Heart and Vascular Institute.

Key Points: 
  • Va., July 9, 2021 /PRNewswire/ -- Anthony P. Morise is being recognized by Continental Who's Who as a Trusted Cardiologist for his exceptional work in the field of Lipidology and Cardiology and in recognition of his work at West Virginia University Heart and Vascular Institute.
  • Dr. Morise currently works for the West Virginia University Heart and Vascular Institute in Morgantown.
  • Dr. Morise is currently working on several clinical trials involving lipid disorders, and often sees and treats patients who have genetic lipid disorders.
  • Dr. Morise is board-certified in Internal Medicine and Cardiovascular Disease by the American Board of Internal Medicine (ABIM).

National Lipid Association Releases Official Scientific Statement on Genetic Testing in Dyslipidemia

Retrieved on: 
Friday, July 10, 2020
Branches of biology, Medical genetics, Biology, Medicine, Medical tests, Lipids, Genetic counseling, Genetic testing, Dyslipidemia, Lipidology, NLA

JACKSONVILLE, Fla., July 10, 2020 (GLOBE NEWSWIRE) -- The National Lipid Association (NLA) today announced the release of its official scientific statement on the use of genetic testing in the diagnosis and management of patients with dyslipidemia.

Key Points: 
  • JACKSONVILLE, Fla., July 10, 2020 (GLOBE NEWSWIRE) -- The National Lipid Association (NLA) today announced the release of its official scientific statement on the use of genetic testing in the diagnosis and management of patients with dyslipidemia.
  • The statement provides insights and guidance for health care providers seeking to further their understanding of the benefits, risks and patient preferences of genetic testing.
  • The statement delves into the importance of genetic counseling before and after genetic testing and outlines potential limitations of genetic testing in dyslipidemia.
  • The manuscript, titled Genetic Testing in Dyslipidemia: A Scientific Statement from the National Lipid Association is in press with the Journal of Clinical Lipidology and can be accessed through the journal or at National Lipid Associations website at www.lipid.org.